Keros Therapeutics
Small molecule therapeutics for hematological, pulmonary, and cardiovascular diseases
- Sector
- Biotech
- Headquarters
- LEXINGTON, MA
- Founded
- 2015
- Latest Form D
- $56M, Mar 2020
- Total capital
- $70.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $70.8M
- 3 Form D · last Mar 2020
- 80 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 18
- 22 pending · first 2021
- Rank in peer group#94 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$56M
- Private capital raisedForm D · SEC · 2nd filing$11.5M
- Private capital raisedForm D · SEC · 1st filing$3.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#94 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jasbir S. SeehraResearcherExecutive Officer, DirectorLinked by 1 patent
- Alon S. LazarusDirectorNamed in SEC Form D filings
- Carl GordonDirectorNamed in SEC Form D filings
- Claudia OrdonezExecutive OfficerNamed in SEC Form D filings
- Jenn LacheyExecutive OfficerNamed in SEC Form D filings
- Julius S. KnowlesDirectorNamed in SEC Form D filings
Show all 11 people
- Keith RegnanteExecutive OfficerNamed in SEC Form D filings
- Nima FarzanDirectorNamed in SEC Form D filings
- Ohad S. HammerDirectorNamed in SEC Form D filings
- Ran NussbaumDirectorNamed in SEC Form D filings
- Zafrira S. AvnurDirectorNamed in SEC Form D filings
What it has protected
USPTO · 18 granted of 40- New patentMethods Of Treating Cardiovascular-related DiseaseUSPTOUS 12,766,147
- PendingMethods Of Treating Iron OverloadUSPTOApplication 19328461
- PendingMethods Of Using Activin Receptor Type II VariantsUSPTOApplication 19390938
Show all 40 patent records
- Methods Of Treating Cardiovascular-related DiseaseOct 20, 2026 · US 12,766,147Granted
- Methods Of Treating Iron OverloadSep 3, 2026 · Application 19328461Pending
- Methods Of Using Activin Receptor Type II VariantsMay 7, 2026 · Application 19390938Pending
- Methods Of Using Activin Receptor Type Iib VariantsApr 23, 2026 · Application 19331002Pending
- Activin Receptor Type II Chimeras And Methods Of Use ThereofApr 9, 2026 · Application 19415215Pending
- Activin Receptor Type Iia Variants And Methods Of Use ThereofMar 24, 2026 · US 12,582,700Granted
- Methods Of Using Activin Receptor Type II VariantsMar 19, 2026 · Application 19390200Pending
- Gdnf Fusion Polypeptides And Methods Of Use ThereofJan 22, 2026 · Application 19287981Pending
- Activin Receptor Type II Chimeras And Methods Of Use ThereofJan 13, 2026 · US 12,522,646Granted
- Methods Of Using ALK2 InhibitorsDec 30, 2025 · US 12,508,262Granted
- Methods Of Treating Iron Overload With A Bmp InhibitorNov 4, 2025 · US 12,458,693Granted
- Methods Of Using Activin Receptor Type Iib VariantsOct 14, 2025 · US 12,440,539Granted
- Activin Receptor Type Iia Variants And Methods Of Use ThereofOct 9, 2025 · Application 19244381Pending
- Methods Of Using ALK2 And ALK3 AntibodiesSep 11, 2025 · Application 18289039Pending
- Gdnf Fusion Polypeptides And Methods Of Use ThereofSep 2, 2025 · US 12,404,313Granted
- Activin Receptor Type II Chimeras And Methods Of Use ThereofAug 28, 2025 · Application 19204105Pending
- ALK2 Antibodies And Methods Of Use ThereofAug 28, 2025 · Application 19207888Pending
- Activin Receptor Type Iia Variants And Methods Of Use ThereofJul 22, 2025 · US 12,364,737Granted
- Activin Receptor Type Iia Variants And Methods Of Use ThereofJul 8, 2025 · US 12,350,313Granted
- Activin Receptor Type Iib Variants And Methods Of Use ThereofJun 26, 2025 · Application 19077471Pending
- ALK2 Antibodies And Methods Of Use ThereofJun 17, 2025 · US 12,331,124Granted
- Methods Of Administering An Activin Receptor Type Iib VariantJun 12, 2025 · Application 19067565Pending
- Activin Receptor Type Iib Variants And Methods Of Use ThereofApr 8, 2025 · US 12,269,858Granted
- Methods Of Using ALK2 InhibitorsJan 30, 2025 · Application 18706647Pending
- Crystal Forms Of An ALK2 InhibitorAug 27, 2024 · US 12,071,438Granted
- Methods Of Using Activin Receptor Type II Signaling InhibitorsAug 1, 2024 · Application 18443987Pending
- Activin Receptor Type II Chimeras And Methods Of Use ThereofJul 11, 2024 · Application 18289037Pending
- Methods Of Using Activin Receptor Type II Signaling InhibitorsJul 4, 2024 · Application 18390085Pending
- Gdnf Fusion Polypeptides And Methods Of Use ThereofFeb 27, 2024 · US 11,912,750Granted
- Activin Receptor Type Iib Variants And Methods Of Use ThereofJan 30, 2024 · US 11,884,715Granted
- Methods Of Treating Cardiovascular-related DiseaseDec 14, 2023 · Application 18139477Pending
- Methods Of Treating LymphopeniaNov 23, 2023 · Application 18140141Pending
- Methods Of Using Activin Receptor Type II VariantsNov 2, 2023 · Application 18128465Pending
- Methods Of Using Activin Receptor Type Iia VariantsAug 24, 2023 · Application 17945324Pending
- Nucleic Acid Molecules Encoding Activin Receptor Type Iia VariantsAug 8, 2023 · US 11,717,558Granted
- Activin Receptor Type Iia Variants And Methods Of Use ThereofNov 1, 2022 · US 11,484,573Granted
- Activin Receptor Type Iia Variants And Methods Of Use ThereofAug 17, 2021 · US 11,090,361Granted
- Activin Receptor Type Iia Variants And Methods Of Use ThereofMay 25, 2021 · US 11,013,785Granted
- Methods Of Using Activin Receptor Type II ChimerasApplication 63617021Pending
- Methods Of Using Activin Receptor Type II Signaling InhibitorsApplication PCTUS2024058808Pending
Related companies, and why
- Cyrano Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Salarius Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Cellino Biotech IncSimilar federal contract value in Biotech · null in contracts
- TheraCea Pharma LCSimilar federal contract value in Biotech · null in contracts
- SightStream Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- KAIO Therapy, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .